All In Biotech

Free tool

FAERS Monitor: Zavesca

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021348 or its brand name (Zavesca, Miglustat). Reports on generic versions are filed under their own applications.

Reports

1,085

Serious

967

89% of reports

Hospitalization

406

Death reported

311

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea163
  • death153
  • seizure112
  • niemann-pick disease97
  • weight decreased97
  • pneumonia86
  • disease progression85
  • tremor75
  • condition aggravated74
  • off label use73
  • dysphagia66
  • pyrexia61
  • epilepsy44
  • vomiting44
  • convulsion43

Reports by year received

View as table
YearReports
200410
200513
200611
20079
200811
20096
201056
201156
201286
201370
201455
201589
201674
201781
201883
201952
202052
2021115
202228
202333
202427
202540
202628

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,074 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
niemann-pick diseaseSignal9785552.954062.21,518,397
epilepsySignal4427.920.91,116
seizureSignal11218.815.81,880
convulsionSignal4314.610.9532
disease progressionSignal8513.911.41,013
dysphagiaSignal6613.510.7753
tremorSignal758.87.0512
weight decreasedSignal976.75.6474
pneumoniaSignal865.24.2288
diarrhoeaSignal1634.94.2517
condition aggravatedSignal744.73.8216
deathSignal1533.43.0274
pyrexiaSignal613.42.7104
vomiting441.81.416
off label use731.61.317

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.